Company intelligence / Profile preview

MIM Corporation

Elmsford, New York, United Statesmimpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

In Q1 2001, the company reported a 400% increase in net income to $3.5 million and a 300% increase in EBITDA to $5.2 million compared to the same period in 2000[5]

Therapeutic areas: ImmunologyNeurologyInfectious Diseases
Modalities: Herbal and nature-based solutions
Industry: Biotech

Drug pipeline

1 asset

Saliravira

Commercial

Indications: COVID-19

Beyond the preview

Go deeper on MIM Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIM Corporation.

Explore the full profile